11月28日,科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗(sac-TMT,佳泰莱®)单药治疗晚期或转移性尿路上皮癌(UC)患者的临床研究数据荣登国际知名学术期刊Annals of Oncology(《肿瘤学年鉴》,影响因子IF=65.4)。这项研究首次证实了芦康沙妥珠单抗(sac-TMT)在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗(sac-...
Source Link11月28日,科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗(sac-TMT,佳泰莱®)单药治疗晚期或转移性尿路上皮癌(UC)患者的临床研究数据荣登国际知名学术期刊Annals of Oncology(《肿瘤学年鉴》,影响因子IF=65.4)。这项研究首次证实了芦康沙妥珠单抗(sac-TMT)在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗(sac-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.